<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811040</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-536-5816</org_study_id>
    <nct_id>NCT04811040</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of GS-5423 and GS-2872 in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection</brief_title>
  <official_title>A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of a&#xD;
      combination of the broadly neutralizing antibodies (bNAbs) GS-5423 and GS-2872 in combination&#xD;
      with the HIV capsid inhibitor lenacapavir (LEN).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Clinical pharmacologist and sponsor are not masked to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>First dose date up to Week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 52 as Determined by the US FDA-defined Snapshot Algorithm</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Positive Anti-GS-5423 Antibodies</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Positive Anti-GS-5423 Antibodies</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Positive Anti-GS-2872 Antibodies</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Positive Anti-GS-2872 Antibodies</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CD4+ Cell Count at Week 26</measure>
    <time_frame>Baseline; Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CD4+ Cell Count at Week 52</measure>
    <time_frame>Baseline; Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Develop Treatment-Emergent Resistance to Lenacapvir (LEN), GS-5423, and GS-2872</measure>
    <time_frame>Day 1 up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)</measure>
    <time_frame>First dose date up to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)</measure>
    <time_frame>First dose date up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Severe Adverse Events (SAEs)</measure>
    <time_frame>First dose date up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUC0-t of GS-5423, and GS-2872, and LEN</measure>
    <time_frame>Day 1 up to Week 52</time_frame>
    <description>AUC0-t is defined as the concentration of drug over time from time zero to time &quot;t&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUClast of GS-5423, and GS-2872, and LEN</measure>
    <time_frame>Day 1 up to Week 52</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: T1/2 of GS-5423, and GS-2872, and LEN</measure>
    <time_frame>Day 1 up to Week 52</time_frame>
    <description>T1/2 is defined as the estimate of the terminal elimination half-life of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax of GS-5423, and GS-2872, and LEN</measure>
    <time_frame>Day 1 up to Week 52</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Tmax of GS-5423, and GS-2872, and LEN</measure>
    <time_frame>Day 1 up to Week 52</time_frame>
    <description>Tmax is defined as the time (observed time point) of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Tlast of GS-5423, and GS-2872, and LEN</measure>
    <time_frame>Day 1 up to Week 52</time_frame>
    <description>Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Ct of GS-5423, and GS-2872, and LEN</measure>
    <time_frame>Day 1 up to Week 52</time_frame>
    <description>Ct is the concentration at a particular time (t).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Lenacapavir (LEN), GS-5423, GS-2872 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will begin treatment by receiving LEN Dose A + LEN Dose B + GS-5423 + GS-2872 Dose C followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + GS-5423 + GS-2872 Dose C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEN, GS-5423, GS-2872 Dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will begin treatment by receiving LEN Dose A + LEN Dose B + GS-5423 + GS-2872 Dose D followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + GS-5423 + GS-2872 Dose D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Lenacapavir</intervention_name>
    <description>Tablets administered without regard to food</description>
    <arm_group_label>LEN, GS-5423, GS-2872 Dose D</arm_group_label>
    <arm_group_label>Lenacapavir (LEN), GS-5423, GS-2872 Dose C</arm_group_label>
    <other_name>GS-6207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous Lenacapavir</intervention_name>
    <description>Administered in the abdomen via subcutaneous injections</description>
    <arm_group_label>LEN, GS-5423, GS-2872 Dose D</arm_group_label>
    <arm_group_label>Lenacapavir (LEN), GS-5423, GS-2872 Dose C</arm_group_label>
    <other_name>GS-6207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5423</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>LEN, GS-5423, GS-2872 Dose D</arm_group_label>
    <arm_group_label>Lenacapavir (LEN), GS-5423, GS-2872 Dose C</arm_group_label>
    <other_name>3BNC117-LS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-2872</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>LEN, GS-5423, GS-2872 Dose D</arm_group_label>
    <arm_group_label>Lenacapavir (LEN), GS-5423, GS-2872 Dose C</arm_group_label>
    <other_name>10-1074-LS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  On first-line antiretroviral therapy (ART) for ≥ 2 years prior to screening. A change&#xD;
             in ART regimen ≥ 28 days prior to screening for reasons other than virologic failure&#xD;
             (VF) (eg, tolerability, simplification, drug-drug interaction profile) is allowed&#xD;
&#xD;
          -  No documented historical resistance to the current ART regimen&#xD;
&#xD;
          -  Plasma HIV-1 RNA &lt; 50 copies/mL at screening&#xD;
&#xD;
          -  Documented plasma HIV-1 RNA &lt; 50 copies/mL for ≥ 18 months preceding the screening&#xD;
             visit (or undetectable HIV-1 RNA level according to the local assay being used if the&#xD;
             limit of detection is ≥ 50 copies/mL). Unconfirmed virologic elevations of ≥ 50&#xD;
             copies/mL (transient detectable viremia, or &quot;blip&quot;) prior to screening are acceptable.&#xD;
&#xD;
          -  Proviral phenotypic sensitivity to both GS-5423 and GS-2872 at screening&#xD;
&#xD;
          -  CD4+ count nadir ≥ 350 cells/μL&#xD;
&#xD;
          -  Screening CD4+ count ≥ 500 cells/μL&#xD;
&#xD;
          -  Availability of a fully active alternative ART regimen, in the opinion of the&#xD;
             investigator, in the event of discontinuation of the current ART regimen with&#xD;
             development of resistance&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Comorbid condition requiring ongoing immunosuppression&#xD;
&#xD;
          -  Evidence of current hepatitis B virus (HBV) infection&#xD;
&#xD;
          -  Evidence of current hepatitis C virus (HCV) infection (prior infection cleared&#xD;
             spontaneously or with treatment is acceptable)&#xD;
&#xD;
          -  History of opportunistic infection or illness indicative of Stage 3 HIV disease&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruane Clinical Research Group Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mills Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>One Community Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95811</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UCSD AntViral Research Center (AVRC)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Yale University; School of Medicine; AIDS Program</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine Schiff Center for Liver Disease</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Indiana CTSI Clinical Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health/Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AXCES Research Group</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai-Clinical and Translational Research Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NC TraCS Institute-CTRC; University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Brody School of Medicine at East Carolina University, ECU Adult Specialty Care</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Crofoot Research, INC.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter Shalit, M.D.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

